التاريخ:	--/--/-- --:--:--
مُعرِّف الحدث:	E5KSF3P6O
نوع الإجراء:	ACQUISITION
حالة الإجراء:	ANNOUNCED
رمز سهم الشركة المستحوِذة:
الرمز المُستهدَف:	ACLX
مُحدَّث:	--/--/-- --:--:--
سعر شراء السهم:	115
عملة سعر السهم الواحد:	USD
مصادر الأخبار:	https://www.businesswire.com/news/home/20260222105602/en/

ملاحظات حول الإجراء

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.